Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jonasch

Showing results (201-210 of 271) with videos related to

Pageof 28
Sort By:
Cell|August 13, 2016
Dual Chromatin and Cytoskeletal Remodeling by SETD2In Young Park, Reid T Powell, Durga Nand Tripathi, et al.
BMC Cancer|July 18, 2018
AKT isoform-specific expression and activation across cancer lineagesJue Wang, Wei Zhao, Huifang Guo, et al.
Cell|May 21, 2021
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesAleksandar Obradovic, Nivedita Chowdhury, Scott M Haake, et al.
Molecular Cancer Research : MCR|May 29, 2012
State of the science: an update on renal cell carcinomaEric Jonasch, P Andrew Futreal, Ian J Davis, et al.
European Urology|July 20, 2017
Recommendations for the Management of Rare Kidney CancersRachel H Giles, Toni K Choueiri, Daniel Y Heng, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Neoplasia (New York, N.Y.)|December 1, 2017
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast DifferentiationTianhong Pan, Song-Chang Lin, Kai-Jie Yu, et al.
Blood|July 26, 2003
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumorsNaoto T Ueno, Yee Chung Cheng, Gabriela Rondón, et al.
Ophthalmology|June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 StudyHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Pageof 28

Showing results (201-210 of 271) with videos related to

Sort By:
Pageof 28
Cell|August 13, 2016
Dual Chromatin and Cytoskeletal Remodeling by SETD2In Young Park, Reid T Powell, Durga Nand Tripathi, et al.
BMC Cancer|July 18, 2018
AKT isoform-specific expression and activation across cancer lineagesJue Wang, Wei Zhao, Huifang Guo, et al.
Cell|May 21, 2021
Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophagesAleksandar Obradovic, Nivedita Chowdhury, Scott M Haake, et al.
Molecular Cancer Research : MCR|May 29, 2012
State of the science: an update on renal cell carcinomaEric Jonasch, P Andrew Futreal, Ian J Davis, et al.
European Urology|July 20, 2017
Recommendations for the Management of Rare Kidney CancersRachel H Giles, Toni K Choueiri, Daniel Y Heng, et al.
BJUI Compass|April 27, 2022
Multimodal kidney-preserving approach in localised and locally advanced high-risk upper tract urothelial carcinomaOmar Alhalabi, Matthew T Campbell, Lianchun Xiao, et al.
The Oncologist|June 23, 2025
Phase 1b/2 study of batiraxcept alone and in combination with cabozantinib with or without nivolumab for advanced clear cell renal cell carcinomaKathryn E Beckermann, Neil J Shah, Matthew T Campbell, et al.
Neoplasia (New York, N.Y.)|December 1, 2017
BIGH3 Promotes Osteolytic Lesions in Renal Cell Carcinoma Bone Metastasis by Inhibiting Osteoblast DifferentiationTianhong Pan, Song-Chang Lin, Kai-Jie Yu, et al.
Blood|July 26, 2003
Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumorsNaoto T Ueno, Yee Chung Cheng, Gabriela Rondón, et al.
Ophthalmology|June 7, 2024
Oral Hypoxia-Inducible Factor 2α Inhibitor Belzutifan in Ocular von Hippel-Lindau Disease: Subgroup Analysis of the Single-Arm Phase 2 LITESPARK-004 StudyHenry E Wiley, Ramaprasad Srinivasan, Jodi K Maranchie, et al.
Pageof 28